An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN)

Blood

Volumn 90, Issue 8, 1997, Pages 3067-3072

  Van 'T Veer, Cornelis ^b   Golden, Neal J ^b   Kalafatis, Michael ^b   Simioni, Paolo ^b   Bertina, Rogier M ^b   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; THROMBIN; THROMBOMODULIN;

ARTICLE; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; GENE MUTATION; GENOTYPE; HEMOPHILIA; HEMOPHILIA A; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0345627213     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.8.3067     Document Type: Article

References (37)

1. Osterud B, Rapaport SI: Activation of factor IX by the reaction product of tissue-factor and factor VII: Additional pathway for initiating coagulation. Proc Natl Acad Sci USA 74:5260, 1977
2. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30:10363, 1991
3. Mann KG, Krishnaswamy S, Lawson JH: Surface dependent hemostasis. Semin Hematol 29:213, 1992
4. Rapaport SI: The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 66:6, 1991
5. Oslou ST, Bjork I, Shore JD: Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Meth Enzym 222:525, 1993
6. Tollefsen DM: Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 74:1209,1995
7. Esmon CT: Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 9:946, 1995
8. Suzuki K, Stenflo J, Dählback B, Teodorsson B: Inactivation of human coagulation factor V by activated protein C. J Biol Chem 258:1914, 1983
9. Solymoss S, Tucker MM, Tracy PB: Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 263:14884, 1988
10. Vehar GA, Davie EW: Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 19:401, 1980
11. Marlar RW, Kleiss AJ, Griffin JH: Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 59:1067, 1982
12. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of human coagulation factor VIII procoagulant protein by activated human protein C and its analogy with factor Va. Blood 63:486, 1984
13. Eaton D, Rodriguez H, Vehar GA: Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25:505, 1986
14. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN: Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82:1236, 1988
15. Berg LP, Varon D, Martinowitz U, Wieland K, Kakkar VV, Cooper DN: Combined factor VIII/factor XI deficiency may cause intra-familial clinical variability in haemophilia A among Askenazi Jews. Blood Coagul Fibrinolysis 5:59, 1994
16. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM: Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84:1031, 1994
17. Zoller B, Berntsdotter A, de Frutos PG, Dahlback B: Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. Blood 85:3518, 1995
18. leiden. Arterioscl Thromb Vasc Biol 15:2181, 1995
19. Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, Hoyer L, Kaufman RJ, Ginsburg D: Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 88:1183, 1996
20. Dahlbäck B, Carlsson M, Svensson P: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a coafactor to activated protein C. Proc Natl Acad Sci USA 90:1004, 1993
21. Bertina R M, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994
22. R506Q. J Biol Chem 270:4053, 1995
23. Lawson JH, Kalafatis M, Stram S, Mann KG: A model for the tissue factor pathway to thrombin. I: An empirical study. J Biol Chem 269:23357, 1994
24. van 't Veer C, Mann KG: Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III and heparin cofactor-II. J Biol Chem 272:4367, 1997
25. van 't Veer C, Golden N, Kalafatis M, Mann KG: Inhibitory mechanism of the protein C pathway on tissue factor induced thrombin generation. Synergistic effect in combination with TFPI. J Biol Chem 272:7983, 1997
26. Bajaj SP, Rapaport SI, Prodanos C: A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 11:397, 1981
27. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG: Isolation of functional coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA 78:162, 1981
28. Griffith MJ, Noyes CM, Church FC: Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 260:2218, 1985
29. Hoyer LW: Hemophilia A. N Engl J Med 330:38, 1994
30. Chan J, Weinman AF, Thompson AR: Factor V Arg/Gln 506 has no dominant influence on the severity of hemophilia when inherited concurrently. Thromb Haemost 73:1793a, 1995 (suppl 1)
31. Arbini AA, Mannucci PM, Bauer KA: Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost 74:1255, 1995
32. Nichols WC, Seligson U, Zivelin A, Terry VH, Arnold ND, Siemieniak DR, Kaufman RJ, Ginsburg D: Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping. J Clin Invest 99:596, 1997
33. Hovig T, Dodds WJ, Rowsell HC, Mustard JF: The transformation of haemostatic platelet plugs in normal and factor IX deficient dogs. Am J Pathol 53:355, 1968
34. Sixma JJ, van den Berg A: The haemostatic plug in haemophilia A: A morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Brit J Heamatol 58:741, 1984
35. Rand MD, Lock JB, van 't Veer C, Gaffney DP, Mann KG: Blood clotting in minimally altered whole blood. Blood 88:3432, 1996
36. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270:14477, 1995
37. Leiden. J Biol Chem 271:22949, 1996